Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that is has begun dosing study participants with ACH-3422, Achillion’s proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial. ACH-3422 is being developed for use in combination regimens to treat chronic hepatitis C viral infection (HCV). Achillion also announced the initiation of dosing in a Phase 2 pilot study evaluating ACH-3102, Achillion’s second-generation NS5A inhibitor, in combination with sofosbuvir for eight and potentially six weeks of treatment for patients with chronic genotype 1 treatment-naive HCV. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares after opening at $2.70 moved to $2.87 on last trade day and at the end of the day closed at $2.85 . Company price to cash ratio in past twelve months was calculated as 2.26. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) showed a negative weekly performance of -7.47%.
ZIOPHARM Oncology, Inc (NASDAQ:ZIOP) a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares advanced 5.26% in last trading session and ended the day on $3.60. ZIOP return on equity ratio is recorded as -207.30% and its return on assets is -108.70%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) yearly performance is 114.29%.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced that Idenix management will host a fireside chat at the Deutsche Bank Securities 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 3:30 p.m. ET at the InterContinental in Boston, MA. Idenix management will also present a corporate overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 8:00 a.m. PT at the Encore at the Wynn in Las Vegas, NV, and at the 2014 UBS Global Healthcare Conference on Monday, May 19, 2014 at 8:00 a.m. ET at the Sheraton New York Hotel in New York, NY. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares moved up 5.76% in last trading session and was closed at $5.51 while trading in range of $5.03 – $5.52 – Idenix Pharmaceuticals Inc (NASDAQ:IDIX) year to date (YTD) performance is -7.86%.
22nd Century Group, Inc. (NYSE MKT:XXII) announced that the Company filed a Form S-3 shelf registration statement on April 18th with the U.S. Securities and Exchange Commission (“SEC”). Upon SEC approval, the universal shelf registration will allow, but not compel, 22nd Century Group to raise up to $45 million of capital over a three-year period through a wide array of securities at amounts and at increments to be determined by the Company. 22nd Century Group Inc (NYSEMKT:XXII) weekly performance is 13.56%. On last trading day company shares ended up $2.68. 22nd Century Group Inc (NYSEMKT:XXII) distance from 50-day simple moving average (SMA50) is -25.08 %. Analysts mean target price for the company is $9.00.
Leave a Reply